448 related articles for article (PubMed ID: 9849963)
1. A novel natural mutation in the thyroid hormone receptor defines a dual functional domain that exchanges nuclear receptor corepressors and coactivators.
Tagami T; Gu WX; Peairs PT; West BL; Jameson JL
Mol Endocrinol; 1998 Dec; 12(12):1888-902. PubMed ID: 9849963
[TBL] [Abstract][Full Text] [Related]
2. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone.
Safer JD; Cohen RN; Hollenberg AN; Wondisford FE
J Biol Chem; 1998 Nov; 273(46):30175-82. PubMed ID: 9804773
[TBL] [Abstract][Full Text] [Related]
3. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors.
Liu Y; Takeshita A; Misiti S; Chin WW; Yen PM
Endocrinology; 1998 Oct; 139(10):4197-204. PubMed ID: 9751500
[TBL] [Abstract][Full Text] [Related]
4. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone.
Tagami T; Jameson JL
Endocrinology; 1998 Feb; 139(2):640-50. PubMed ID: 9449636
[TBL] [Abstract][Full Text] [Related]
5. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone.
Ishii S; Yamada M; Satoh T; Monden T; Hashimoto K; Shibusawa N; Onigata K; Morikawa A; Mori M
Mol Endocrinol; 2004 Jul; 18(7):1708-20. PubMed ID: 15131262
[TBL] [Abstract][Full Text] [Related]
6. A novel thyroid hormone receptor-beta mutation that fails to bind nuclear receptor corepressor in a patient as an apparent cause of severe, predominantly pituitary resistance to thyroid hormone.
Wu SY; Cohen RN; Simsek E; Senses DA; Yar NE; Grasberger H; Noel J; Refetoff S; Weiss RE
J Clin Endocrinol Metab; 2006 May; 91(5):1887-95. PubMed ID: 16464943
[TBL] [Abstract][Full Text] [Related]
7. A natural transactivation mutation in the thyroid hormone beta receptor: impaired interaction with putative transcriptional mediators.
Collingwood TN; Rajanayagam O; Adams M; Wagner R; Cavaillès V; Kalkhoven E; Matthews C; Nystrom E; Stenlof K; Lindstedt G; Tisell L; Fletterick RJ; Parker MG; Chatterjee VK
Proc Natl Acad Sci U S A; 1997 Jan; 94(1):248-53. PubMed ID: 8990194
[TBL] [Abstract][Full Text] [Related]
8. Impaired interaction of mutant thyroid hormone receptors associated with human hepatocellular carcinoma with transcriptional coregulators.
Lin KH; Wu YH; Chen SL
Endocrinology; 2001 Feb; 142(2):653-62. PubMed ID: 11159836
[TBL] [Abstract][Full Text] [Related]
9. Resistance to thyroid hormone caused by two mutant thyroid hormone receptors beta, R243Q and R243W, with marked impairment of function that cannot be explained by altered in vitro 3,5,3'-triiodothyroinine binding affinity.
Yagi H; Pohlenz J; Hayashi Y; Sakurai A; Refetoff S
J Clin Endocrinol Metab; 1997 May; 82(5):1608-14. PubMed ID: 9141558
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.
Jeyakumar M; Tanen MR; Bagchi MK
Mol Endocrinol; 1997 Jun; 11(6):755-67. PubMed ID: 9171239
[TBL] [Abstract][Full Text] [Related]
11. The nuclear corepressors recognize distinct nuclear receptor complexes.
Cohen RN; Putney A; Wondisford FE; Hollenberg AN
Mol Endocrinol; 2000 Jun; 14(6):900-14. PubMed ID: 10847591
[TBL] [Abstract][Full Text] [Related]
12. A novel TR beta mutation (R383H) in resistance to thyroid hormone syndrome predominantly impairs corepressor release and negative transcriptional regulation.
Clifton-Bligh RJ; de Zegher F; Wagner RL; Collingwood TN; Francois I; Van Helvoirt M; Fletterick RJ; Chatterjee VK
Mol Endocrinol; 1998 May; 12(5):609-21. PubMed ID: 9605924
[TBL] [Abstract][Full Text] [Related]
13. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential.
Harrus D; Déméné H; Vasquez E; Boulahtouf A; Germain P; Figueira AC; Privalsky ML; Bourguet W; le Maire A
Thyroid; 2018 Dec; 28(12):1708-1722. PubMed ID: 30235988
[TBL] [Abstract][Full Text] [Related]
14. The interaction of the vitamin D receptor with nuclear receptor corepressors and coactivators.
Tagami T; Lutz WH; Kumar R; Jameson JL
Biochem Biophys Res Commun; 1998 Dec; 253(2):358-63. PubMed ID: 9878542
[TBL] [Abstract][Full Text] [Related]
15. The thyroid hormone receptor variant alpha2 is a weak antagonist because it is deficient in interactions with nuclear receptor corepressors.
Tagami T; Kopp P; Johnson W; Arseven OK; Jameson JL
Endocrinology; 1998 May; 139(5):2535-44. PubMed ID: 9564869
[TBL] [Abstract][Full Text] [Related]
16. Very strong correlation between dominant negative activities of mutant thyroid hormone receptors and their binding avidity for corepressor SMRT.
Matsushita A; Misawa H; Andoh S; Natsume H; Nishiyama K; Sasaki S; Nakamura H
J Endocrinol; 2000 Dec; 167(3):493-503. PubMed ID: 11115777
[TBL] [Abstract][Full Text] [Related]
17. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation.
Nomura Y; Nagaya T; Tsukaguchi H; Takamatsu J; Seo H
Endocrinology; 1996 Oct; 137(10):4082-6. PubMed ID: 8828460
[TBL] [Abstract][Full Text] [Related]
18. A fusion protein of the estrogen receptor (ER) and nuclear receptor corepressor (NCoR) strongly inhibits estrogen-dependent responses in breast cancer cells.
Chien PY; Ito M; Park Y; Tagami T; Gehm BD; Jameson JL
Mol Endocrinol; 1999 Dec; 13(12):2122-36. PubMed ID: 10598586
[TBL] [Abstract][Full Text] [Related]
19. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone.
Ng L; Forrest D; Haugen BR; Wood WM; Curran T
Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112
[TBL] [Abstract][Full Text] [Related]
20. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone.
Collingwood TN; Wagner R; Matthews CH; Clifton-Bligh RJ; Gurnell M; Rajanayagam O; Agostini M; Fletterick RJ; Beck-Peccoz P; Reinhardt W; Binder G; Ranke MB; Hermus A; Hesch RD; Lazarus J; Newrick P; Parfitt V; Raggatt P; de Zegher F; Chatterjee VK
EMBO J; 1998 Aug; 17(16):4760-70. PubMed ID: 9707435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
